Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain

Neuroscience

Volumn 189, Issue , 2011, Pages 345-358

  Kupershmidt, L ^a   Weinreb, O ^a   Amit, T ^a   Mandel, S ^a   Bar Am, O ^a   Youdim, M B H ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Yonsei University   (South Korea)

Author keywords

Brain derived neurotrophic factor; Hypoxia inducible factor; Iron chelation; Multifunctional drug; Pro survival signaling pathways; Systemic chronic administration

Indexed keywords

5 (N METHYL N PROPARGYAMINOMETHYL) 8 HYDROXYQUINOLINE; BRAIN DERIVED NEUROTROPHIC FACTOR; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; ENOLASE; ERYTHROPOIETIN; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GLUCOSE TRANSPORTER 1; GLUTATHIONE PEROXIDASE; GLYCOGEN SYNTHASE KINASE 3BETA; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INDUCIBLE NITRIC OXIDE SYNTHASE; IRON; IRON CHELATING AGENT; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; PROTEIN KINASE C; TRANSFERRIN RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN REGION; CELL SURVIVAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG TARGETING; ENZYME PHOSPHORYLATION; HIPPOCAMPUS; IMMUNOBLOTTING; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPINAL CORD; UPREGULATION;

ANIMALS; ANTIOXIDANTS; BRAIN; GENE EXPRESSION PROFILING; HYDROXYQUINOLINES; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IRON CHELATING AGENTS; LIVER; MICE; MYOCARDIUM; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SPINAL CORD;

EID: 79960895695     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2011.03.040     Document Type: Article

References (55)

1. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., Laughton K., Li Q.X., Charman S.A., Nicolazzo J.A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C.W., Tanzi R.E., Cappai R., Masters C.L., Barnham K.J., Bush A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59:43-55.
2. Amit T., Avramovich-Tirosh Y., Youdim M.B., Mandel S. Targeting multiple Alzheimer's disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J 2008, 22:1296-1305.
3. Avramovich-Tirosh Y., Bar-Am O., Amit T., Youdim M.B., Weinreb O. Up-regulation of Hypoxia-Inducible Factor (HIF)-1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr Alzheimer Res 2010, 7:300-306.
4. Avramovich-Tirosh Y., Amit T., Bar-Am O., Zheng H., Fridkin M., Youdim M.B. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 2007, 100:490-502.
5. Avramovich-Tirosh Y., Reznichenko L., Mit T., Zheng H., Fridkin M., Weinreb O., Mandel S., Youdim M.B. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 2007, 4:403-411.
6. Bar-Am O., Amit T., Youdim M.B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004, 355:169-172.
7. Bar-Am O., Yogev-Falach M., Amit T., Sagi Y., Youdim M.B. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J Neurochem 2004, 89:1119-1125.
8. Bernhardt W.M., Warnecke C., Willam C., Tanaka T., Wiesener M.S., Eckardt K.U. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 2007, 435:221-245.
9. Bush A.I. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 2008, 15:223-240.
10. Carrillo M.C., Minami C., Kitani K., Maruyama W., Ohashi K., Yamamoto T., Naoi M., Kanai S., Youdim M.B. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 2000, 67:577-585.
11. Cherny R.A., Legg J.T., McLean C.A., Fairlie D.P., Huang X., Atwood C.S., Beyreuther K., Tanzi R.E., Masters C.L., Bush A.I. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999, 274:23223-23228.
12. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
13. Correia S.C., Moreira P.I. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration?. J Neurochem 2010, 112:1-12.
14. Dongiovanni P., Valenti L., Ludovica Fracanzani A., Gatti S., Cairo G., Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am J Pathol 2008, 172:738-747.
15. Gal S., Zheng H., Fridkin M., Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neurochem 2005, 95:79-88.
16. Gal S., Zheng H., Fridkin M., Youdim M.B. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 2010, 17:15-27.
17. Hamrick S.E., McQuillen P.S., Jiang X., Mu D., Madan A., Ferriero D.M. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. Neurosci Lett 2005, 379:96-100.
18. Harten S.K., Ashcroft M., Maxwell P.H. Prolyl hydroxylase domain inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox Signal 2010, 12:459-480.
19. Hurn P.D., Koehler R.C., Blizzard K.K., Traystman R.J. Deferoxamine reduces early metabolic failure associated with severe cerebral ischemic acidosis in dogs. Stroke 1995, 26:688-695.
20. Jaakkola P., Mole D.R., Tian Y.M., Wilson M.I., Gielbert J., Gaskell S.J., Kriegsheim A., Hebestreit H.F., Mukherji M., Schofield C.J., Maxwell P.H., Pugh C.W., Ratcliffe P.J. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
21. Kitani K., Minami C., Maruyama W., Kanai S., Ivy G.O., Carrillo M.C. Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: implications for the life prolonging effect of (-)deprenyl. J Neural Transm Suppl 2000, 60:139-156.
22. Koh S.H., Kim S.H., Kwon H., Park Y., Kim K.S., Song C.W., Kim J., Kim M.H., Yu H.J., Henkel J.S., Jung H.K. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res Mol Brain Res 2003, 118:72-81.
23. Kupershmidt L., Weinreb O., Amit T., Mandel S., Carri M.T., Youdim M.B. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 2009, 23:3766-3779.
24. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., Wilson J., Ritchie C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 2008, 7:779-786.
25. Lee J.Y., Friedman J.E., Angel I., Kozak A., Koh J.Y. The lipophilic metal chelator DP-109 reduces amyloid pathology in brains of human beta-amyloid precursor protein transgenic mice. Neurobiol Aging 2004, 25:1315-1321.
26. Li Y.X., Ding S.J., Xiao L., Guo W., Zhan Q. Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull 2008, 24:89-95.
27. Maruyama W., Akao Y., Carrillo M.C., Kitani K., Youdium M.B., Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 2002, 24:675-682.
28. Murphy T.H., Schnaar R.L., Coyle J.T. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J 1990, 4:1624-1633.
29. Naoi M., Maruyama W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease. Expert Rev Neurother 2009, 9:1233-1250.
30. Plock J., Frese S., Keogh A., Bisch-Knaden S., Ayuni E., Corazza N., Weikert C., Jakob S., Erni D., Dufour J.F., Brunner T., Candinas D., Stroka D. Activation of non-ischemic, hypoxia-inducible signalling pathways up-regulate cytoprotective genes in the murine liver. J Hepatol 2007, 47:538-545.
31. Prass K., Ruscher K., Karsch M., Isaev N., Megow D., Priller J., Scharff A., Dirnagl U., Meisel A. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 2002, 22:520-525.
32. Risbud M.V., Fertala J., Vresilovic E.J., Albert T.J., Shapiro I.M. Nucleus pulposus cells upregulate PI3K/Akt and MEK/ERK signaling pathways under hypoxic conditions and resist apoptosis induced by serum withdrawal. Spine (Phila Pa 1976) 2005, 30:882-889.
33. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 2003, 60:1685-1691.
34. Rosenberger C., Mandriota S., Jurgensen J.S., Wiesener M.S., Horstrup J.H., Frei U., Ratcliffe P.J., Maxwell P.H., Bachmann S., Eckardt K.U. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol 2002, 13:1721-1732.
35. Shachar D.B., Kahana N., Kampel V., Warshawsky A., Youdim M.B. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lession in rats. Neuropharmacology 2004, 46:254-263.
36. Sharp F.R., Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci 2004, 5:437-448.
37. Siddiq A., Aminova L.R., Ratan R.R. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem Res 2007, 32:931-946.
38. Siddiq A., Ayoub I.A., Chavez J.C., Aminova L., Shah S., LaManna J.C., Patton S.M., Connor J.R., Cherny R.A., Volitakis I., Bush A.I., Langsetmo I., Seeley T., Gunzler V., Ratan R.R. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J Biol Chem 2005, 280:41732-41743.
39. Sung S.M., Jung D.S., Kwon C.H., Park J.Y., Kang S.K., Kim Y.K. Hypoxia/reoxygenation stimulates proliferation through PKC-dependent activation of ERK and Akt in mouse neural progenitor cells. Neurochem Res 2007, 32:1932-1939.
40. Torrance J.D., Bothwell T.H. Tissue iron stores. Methods Haematol 1980, 1:90-115.
41. Treiber C., Simons A., Strauss M., Hafner M., Cappai R., Bayer T.A., Multhaup G. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 2004, 279:51958-51964.
42. Wang G.L., Semenza G.L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993, 82:3610-3615.
43. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann N Y Acad Sci 2007, 1122:155-168.
44. Weinreb O., Amit T., Bar-Am O., Youdim M.B. Rasagiline; a novel anti-parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. Prog Neurobiol 2010, l92:330-344.
45. Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., Youdim M.B. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 2004, 18:1471-1473.
46. Weinreb O., Amit T., Mandel S.A., Kupershmidt L., Youdim M.B. Neuroprotective multifunctional iron chelators: from redox-sensitive process to novel therapeutic opportunities. Antioxid Redox Signal 2010, 13:919-949.
47. White A.R., Du T., Laughton K.M., Volitakis I., Sharples R.A., Xilinas M.E., Hoke D.E., Holsinger R.M., Evin G., Cherny R.A., Hill A.F., Barnham K.J., Li Q.X., Bush A.I., Masters C.L. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metalloprotease activity. J Biol Chem 2006, 281:17670-17680.
48. Youdim M.B., Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 2005, 26:27-35.
49. Yu F., White S.B., Zhao Q., Lee F.S. HIF-1alpha binding to VHL is regulated by stimulus-sensitive proline hydroxylation. Proc Natl Acad Sci U S A 2001, 98:9630-9635.
50. Zaman K., Ryu H., Hall D., O'Donovan K., Lin K.I., Miller M.P., Marquis J.C., Baraban J.M., Semenza G.L., Ratan R.R. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J Neurosci 1999, 19:9821-9830.
51. Zatta P., Drago D., Bolognin S., Sensi S.L. Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 2009, 30:346-355.
52. Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 2004, 5:863-873.
53. Zheng H., Gal S., Weiner L.M., Bar-Am O., Warshawsky A., Fridkin M., Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 2005, 95:68-78.
54. Zheng H., Weiner L.M., Bar-Am O., Epsztejn S., Cabantchik Z.I., Warshawsky A., Youdim M.B., Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 2005, 13:773-783.
55. Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M.B., Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 2007, 21:3835-3844.